Nurix Therapeutics vs Protagonist Therapeutics
NRIX and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NRIX and PTGX compare
Protagonist Therapeutics is the larger company, worth 5.0 times as much as Nurix Therapeutics ($8.5B against $1.7B).
On earnings, Nurix Therapeutics is cheaper: it trades at 6.7× trailing earnings, against 27.7× for Protagonist Therapeutics.
Nurix Therapeutics grew revenue faster over the last twelve months (739% versus 164% for Protagonist Therapeutics).
Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 62.0% compared with 42.0% at Nurix Therapeutics.
Protagonist Therapeutics scores higher on the StockData Score (16 against 15 for Nurix Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NRIX | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $8.5B |
| Share price | $15.48 | $130.95 |
| Change, 1 year | 27.2% | 54.3% |
| Change, 5 years | −50.6% | 274% |
| Beta (5Y) | 1.46 | 0.78 |
| Employees | 317 | 132 |
| StockData Score | ||
| Total score | 15 | 16 (better) |
| Valuation score | 4 | 4 |
| Growth score | 2 | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 6.7× (better) | 27.7× |
| P/S | 2.4× (better) | 15.4× |
| P/B | 1.7× (better) | 7.8× |
| EV/EBITDA | 2.0× (better) | 23.6× |
| P/FCF | 4.6× (better) | 77.6× |
| FCF yield | 21.9% (better) | 1.3% |
| Fair value | $57.66 | $183.25 |
| Margin of safety | 73.2% (better) | 28.5% |
| Growth | ||
| Revenue growth (TTM) | 739% (better) | 164% |
| Revenue growth, 5Y average | 36.3% (better) | 10.0% |
| Net income growth (TTM) | – | 646% |
| EPS growth (TTM) | – | 661% |
| Profitability | ||
| Operating margin | 41.3% | 58.6% (better) |
| Net margin | 42.0% | 62.0% (better) |
| FCF margin | 52.7% (better) | 19.8% |
| Return on equity | 44.0% (better) | 39.6% |
| Return on invested capital | – | 178% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.44 | 19.85 (better) |
| Altman Z-score | 6.10 | 84.88 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −1.1% | – |
| Shareholder yield | −1.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 107% | 117% |
| Held by insiders | 3.2% | 1.7% |
| Insider net buying, 12 months | −$5.2M (better) | −$95.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 17.9% | 16.1% |
Go deeper
- NRIX stock overview
- NRIX income statement
- NRIX valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.